Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis

A hospital-based cohort study

Jun Hakamata, Yuko Kaneko, Mikiko Shimizu, Kunihiro Yamaoka, Junya Maruyama, Tsutomu Takeuchi, Mayumi Mochizuki, Masayuki Hashiguchi

Research output: Contribution to journalArticle

Abstract

Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.

Original languageEnglish
Pages (from-to)1414-1422
Number of pages9
JournalBiological and Pharmaceutical Bulletin
Volume41
Issue number9
Publication statusPublished - 2018 Jan 1

Fingerprint

Methotrexate
Rheumatoid Arthritis
Cohort Studies
Therapeutics
Genotype
Outpatients
Reduced Folate Carrier Protein
Logistic Models
Electronic Health Records
Hydrolases
Genetic Polymorphisms
Single Nucleotide Polymorphism
Real-Time Polymerase Chain Reaction
Multivariate Analysis
Alleles
Observation
Pharmaceutical Preparations

Keywords

  • Effectiveness
  • European League Against Rheumatism
  • Japanese
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis : A hospital-based cohort study. / Hakamata, Jun; Kaneko, Yuko; Shimizu, Mikiko; Yamaoka, Kunihiro; Maruyama, Junya; Takeuchi, Tsutomu; Mochizuki, Mayumi; Hashiguchi, Masayuki.

In: Biological and Pharmaceutical Bulletin, Vol. 41, No. 9, 01.01.2018, p. 1414-1422.

Research output: Contribution to journalArticle

@article{f3bcc16c52d04db8958f5fd5ddec62d2,
title = "Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis: A hospital-based cohort study",
abstract = "Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.",
keywords = "Effectiveness, European League Against Rheumatism, Japanese, Methotrexate, Rheumatoid arthritis",
author = "Jun Hakamata and Yuko Kaneko and Mikiko Shimizu and Kunihiro Yamaoka and Junya Maruyama and Tsutomu Takeuchi and Mayumi Mochizuki and Masayuki Hashiguchi",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "1414--1422",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "9",

}

TY - JOUR

T1 - Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis

T2 - A hospital-based cohort study

AU - Hakamata, Jun

AU - Kaneko, Yuko

AU - Shimizu, Mikiko

AU - Yamaoka, Kunihiro

AU - Maruyama, Junya

AU - Takeuchi, Tsutomu

AU - Mochizuki, Mayumi

AU - Hashiguchi, Masayuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.

AB - Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.

KW - Effectiveness

KW - European League Against Rheumatism

KW - Japanese

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85052717434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052717434&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 1414

EP - 1422

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 9

ER -